SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals's Climate Target Data Preview
As of 2024, SK Biopharmaceuticals has disclosed 2 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 2 absolute reduction targets, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into SK Biopharmaceuticals ’s climate strategy, ambition level, and alignment with global decarbonization goals.
| Target Type | Scope of Target | Unit | Target | Target Year |
|---|---|---|---|---|
Absolute-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2026 |
Absolute-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2030 |
This table provides a simplified preview of selected climate targets data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into SK Biopharmaceuticals's Greenhouse Gas Emissions Pathways
As of 2024, SK Biopharmaceuticals has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions.
Does SK Biopharmaceuticals have a target to reduce the emissions from its operations?
As of 2024, SK Biopharmaceuticals has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources.
SK Biopharmaceuticals's most ambitious operational target is to reduce these emissions by 50% by 2030, compared to a baseline of 1,341 Metric Tonnes of CO2 equivalent (mtCO2e) in 2020.
Instead of reducing operational emissions, SK Biopharmaceuticals has increased them, with 2023 levels exceeding those of the 2020 baseline, placing the company well behind its reduction target.